Quick Answer
BIOMARIN PHARMACEUTICAL INC reported Operating Income Loss of $409.48 million for the year ending 2025.
- BIOMARIN PHARMACEUTICAL INC showed a decrease of -15.4% in Operating Income Loss from 2024 to 2025.
- This data is from BIOMARIN PHARMACEUTICAL INC's annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2008 to 2025 (18 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 18 years of available data (2008 to 2025), BIOMARIN PHARMACEUTICAL INC's Operating Income Loss has grown by 930.0%.
- Historical annual values: Fiscal year 2025: $409.48 million | Fiscal year 2024: $484.21 million | Fiscal year 2023: $185.77 million | Fiscal year 2022: $160.97 million | Fiscal year 2021: -$82.34 million | Fiscal year 2020: -$43.44 million | Fiscal year 2019: -$100.46 million | Fiscal year 2018: -$123.52 million | Fiscal year 2017: -$14.70 million | Fiscal year 2016: -$803.43 million | Fiscal year 2015: -$110.70 million | Fiscal year 2014: -$92.89 million | Fiscal year 2013: -$156.01 million | Fiscal year 2012: -$110.22 million | Fiscal year 2011: -$33.89 million | Fiscal year 2010: $544.0 thousand | Fiscal year 2009: $16.43 million | Fiscal year 2008: $39.76 million.
- Data sourced from SEC EDGAR public filings as of June 21, 2026.
Last verified: